FDA convenes an advisory committee on COMPASS psilocybin before any approval action, centered on durability of remission.

COMPASS Pathways is a company developing a psilocybin-based therapy. Their drug works fast — patients feel better quickly — but scientists aren't sure yet how long that improvement lasts. The FDA (US drug regulator) will likely respond by convening an advisory committee, which is an independent panel of outside experts who review the evidence and give recommendations before any approval decision is made. This adds a step to the approval process and could slow things down.

Rapid remission with uncertain durability is precisely what triggers advisory scrutiny. I won't sign off on hype; the published follow-up gap demands external review.